Shares of Pharming are up $2.45, or 22%, to $13.73 after the company announced that the Food and Drug Administration has approved Joenja for the treatment of activated phosphoinositide 3-kinase delta syndrome, or APDS, in adult and pediatric patients 12 years of age and older.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PHAR: